Analysis of the Economic Burden of Chronic Kidney Disease With Comorbidities Among Patients in Xuzhou, China.

Wan Jie, Minghong Yao, Mingqi Wang, Yuning Wang, Yulong Jia, Yanmei Liu, Kang Zou, Xin Sun
Author Information
  1. Wan Jie: Institute of Integrated Traditional Chinese and Western Medicine and Chinese Evidence-Based Medicine Center and Cochrane China Center and MAGIC China Center, West China Hospital, Sichuan University, Chengdu, China.
  2. Minghong Yao: Institute of Integrated Traditional Chinese and Western Medicine and Chinese Evidence-Based Medicine Center and Cochrane China Center and MAGIC China Center, West China Hospital, Sichuan University, Chengdu, China.
  3. Mingqi Wang: Institute of Integrated Traditional Chinese and Western Medicine and Chinese Evidence-Based Medicine Center and Cochrane China Center and MAGIC China Center, West China Hospital, Sichuan University, Chengdu, China.
  4. Yuning Wang: Institute of Integrated Traditional Chinese and Western Medicine and Chinese Evidence-Based Medicine Center and Cochrane China Center and MAGIC China Center, West China Hospital, Sichuan University, Chengdu, China.
  5. Yulong Jia: Institute of Integrated Traditional Chinese and Western Medicine and Chinese Evidence-Based Medicine Center and Cochrane China Center and MAGIC China Center, West China Hospital, Sichuan University, Chengdu, China.
  6. Yanmei Liu: Institute of Integrated Traditional Chinese and Western Medicine and Chinese Evidence-Based Medicine Center and Cochrane China Center and MAGIC China Center, West China Hospital, Sichuan University, Chengdu, China.
  7. Kang Zou: Institute of Integrated Traditional Chinese and Western Medicine and Chinese Evidence-Based Medicine Center and Cochrane China Center and MAGIC China Center, West China Hospital, Sichuan University, Chengdu, China.
  8. Xin Sun: Institute of Integrated Traditional Chinese and Western Medicine and Chinese Evidence-Based Medicine Center and Cochrane China Center and MAGIC China Center, West China Hospital, Sichuan University, Chengdu, China.

Abstract

Objectives: To analyze the costs and medication patterns of patients with chronic kidney disease (CKD) and comorbidities in Xuzhou, China, using a large electronic medical records database.
Methods: Data were obtained from an electronic medical records database. The annual per-person and per-visit cost of hospitalization, as well as the proportions of those costs, are presented.
Results: The majority of the participants were middle-aged men, and had medical insurance. Glomerulonephritis was the primary cause of CKD in patients with an identified etiology. The average per-visit cost of hospitalization for the CKD-renal anemia and CKD-mineral and bone disorder groups was 8,674.5 (5,154.3-13,949.6) and 8,182.6 (4,798.2-12,844.7) Yuan, respectively, which was greater than that of the other groups. The major expenses incurred were for diagnostics, drug usage, surgical procedures, laboratory tests and material costs.
Conclusion: The substantial burden imposed by CKD with comorbidities indicates the importance of implementing public health strategies aimed at detecting and preventing these conditions in the general population. With the aging population, our nation may experience a greater CKD-related economic burden.

Keywords

References

  1. Kidney Int Suppl (2011). 2020 Dec;10(2):e97-e185 [PMID: 33304640]
  2. Nephrol Dial Transplant. 2012 Oct;27 Suppl 3:iii73-80 [PMID: 22815543]
  3. Nephrology (Carlton). 2019 Jul;24(7):725-736 [PMID: 30198082]
  4. BMJ. 2023 Jul 31;382:e074265 [PMID: 37524389]
  5. N Engl J Med. 2004 Sep 23;351(13):1296-305 [PMID: 15385656]
  6. Adv Exp Med Biol. 2019;1165:3-15 [PMID: 31399958]
  7. Am J Kidney Dis. 2020 Aug;76(2):258-264 [PMID: 31492486]
  8. Am J Kidney Dis. 2011 Aug;58(2):162-5 [PMID: 21664736]
  9. J Am Soc Nephrol. 2019 Feb;30(2):323-335 [PMID: 30606782]
  10. J Am Soc Nephrol. 2020 Jul;31(7):1594-1601 [PMID: 32487562]
  11. N Engl J Med. 2016 Sep 1;375(9):905-6 [PMID: 27579659]
  12. Kidney Int. 2003 Mar;63(3):1121-9 [PMID: 12631096]
  13. JAMA. 2021 Dec 28;326(24):2498-2506 [PMID: 34962526]
  14. Circulation. 2003 Oct 28;108(17):2154-69 [PMID: 14581387]
  15. China CDC Wkly. 2023 Jan 13;5(2):35-39 [PMID: 36776686]
  16. Clin J Am Soc Nephrol. 2023 Jan 1;18(1):60-71 [PMID: 36719159]
  17. BMJ Open. 2020 Jun 30;10(6):e038401 [PMID: 32606067]
  18. Circulation. 2019 Mar 5;139(10):e56-e528 [PMID: 30700139]
  19. J Diabetes. 2017 Apr;9(4):405-411 [PMID: 27194641]
  20. Lancet. 2013 Jul 13;382(9887):158-69 [PMID: 23727165]
  21. JAMA Intern Med. 2016 Apr;176(4):484-93 [PMID: 26954564]
  22. J Nephrol. 2017 Apr;30(2):263-269 [PMID: 27165160]
  23. Lancet. 2020 Feb 29;395(10225):709-733 [PMID: 32061315]
  24. Diabetes Care. 2018 May;41(5):917-928 [PMID: 29567642]
  25. Nephrol Dial Transplant. 2020 Apr 1;35(4):558-564 [PMID: 31028383]
  26. Zhonghua Liu Xing Bing Xue Za Zhi. 2021 Oct 10;42(10):1780-1789 [PMID: 34814612]
  27. Nature. 2020 Mar;579(7800):494-496 [PMID: 32210388]
  28. Ann Intern Med. 2013 Jun 4;158(11):825-30 [PMID: 23732715]

MeSH Term

Humans
Male
China
Middle Aged
Renal Insufficiency, Chronic
Female
Comorbidity
Cost of Illness
Aged
Adult
Hospitalization
Adolescent
Young Adult
Health Care Costs

Word Cloud

Created with Highcharts 10.0.0costsCKDmedicalburdenmedicationpatternspatientschronickidneydiseasecomorbiditiesXuzhouChinaelectronicrecordsdatabaseper-visitcosthospitalizationgroups856greaterexpensespopulationeconomicObjectives:analyzeusinglargeMethods:Dataobtainedannualper-personwellproportionspresentedResults:majorityparticipantsmiddle-agedmeninsuranceGlomerulonephritisprimarycauseidentifiedetiologyaverageCKD-renalanemiaCKD-mineralbonedisorder6741543-1394918247982-128447YuanrespectivelymajorincurreddiagnosticsdrugusagesurgicalprocedureslaboratorytestsmaterialConclusion:substantialimposedindicatesimportanceimplementingpublichealthstrategiesaimeddetectingpreventingconditionsgeneralagingnationmayexperienceCKD-relatedAnalysisEconomicBurdenChronicKidneyDiseaseComorbiditiesAmongPatientscomorbiditycomposition

Similar Articles

Cited By

No available data.